Johns Hopkins ABX Guide
Nevirapine
INDICATIONS
FDA
FDA
- Treatment of HIV infection in combination with other antiretroviral agents.
- Due to the increased risk of hepatitis, avoid starting NVP in women with pre-treatment CD4 >250 and men with CD4 >400.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Single dose at the time of delivery to prevent perinatal transmission (widely used in developing countries, but the risk of NNRTI resistance; combination therapy preferred when available). The risk of hepatitis for women with CD4 >250 does not apply to single-dose NVP.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: October 10, 2023
Citation
, Kathryn Dzintars, Pharm.D. BCPS, and Paul G Auwaerter. "Nevirapine." Johns Hopkins ABX Guide, The Johns Hopkins University, 2023. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540383/all/Nevirapine.
K, Auwaerter PG. Nevirapine. Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540383/all/Nevirapine. Accessed October 31, 2025.
, K., & Auwaerter, P. G. (2023). Nevirapine. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540383/all/Nevirapine
K, Auwaerter PG. Nevirapine [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. [cited 2025 October 31]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540383/all/Nevirapine.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Nevirapine
ID - 540383
A1 - ,Kathryn Dzintars, Pharm.D. BCPS,
AU - Auwaerter,Paul,M.D.
Y1 - 2023/10/10/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540383/all/Nevirapine
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
